<DOC>
	<DOCNO>NCT02198170</DOCNO>
	<brief_summary>The purpose study assess influence simultaneous CYP3A4 p-glycoprotein inhibition lenvatinib pharmacokinetics follow single oral dose 5 mg lenvatinib .</brief_summary>
	<brief_title>A Pharmacokinetic Study Assess Influence Simultaneous CYP3A4 P-glycoprotein Inhibition E7080 Pharmacokinetics Following Single Dose Oral Administration 5 mg E7080 Healthy Volunteers</brief_title>
	<detailed_description>This single-center , randomize , open-label , two-period , crossover study consist two phase : Prerandomization Randomization . The Prerandomization Phase two period : Screening Baseline 1 . The Randomization Phase two period : Treatment Period 1 Treatment Period 2 Baseline 2 assessment prior Treatment Period 2 . In Randomization Phase , subject randomize one two possible treatment sequence ( placebo/ketoconazole ketoconazole/placebo ) . Ketoconazole 400 mg placebo orally administer daily first four day treatment period . On fifth day treatment period , addition ketoconazole/placebo , 5 mg lenvatinib orally administer . Ketoconazole/placebo administration continue 13 additional day . Subjects cross Treatment Period 1 Treatment Period 2 2-week washout .</detailed_description>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Inclusion Criteria 1 . Nonsmoking ( i.e. , use nicotine nicotine containing product within past 3 month ) , male female subject , age great equal 18 year less equal 55 year 2 . Body mass index ( BMI ) great equal 18 less equal 30 kg/m2 screen 3 . All female must negative serum urine BhCG test result Screening Baseline . Females childbearing potential must agree use medically acceptable method contraception ( e.g. , abstinence ; highly effective method intrauterine device [ IUD ] , condom + spermicide condom + diaphragm spermicide , contraceptive implant , oral contraceptive ; vasectomized partner ) throughout entire study period 30 day study drug discontinuation . The subject exempt requirement postmenopausal woman ( define great age 50 least 12 month amenorrhea ) subject sterilize surgically otherwise prove sterile ( e.g. , bilateral tubal ligation surgery least 6 month prior dose , hysterectomy , bilateral oophorectomy surgery least 2 month prior dose ) . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 12 week prior dose must continue use contraceptive study 30 day study drug discontinuation . 4 . Male subject abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use highly effective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , IUD ) start least one menstrual cycle prior start study drug ( ) throughout entire study 30 day last dose study drug . Those partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . 5 . Provide write informed consent 6 . Are willing able comply aspect protocol Exclusion Criteria 1 . Subjects clinically significant illness require medical treatment within 8 week clinically significant infection within 4 week dose 2 . Subjects disease may influence outcome study ; psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism within 4 week prior dose 3 . Subjects history gastrointestinal surgery ( hepatectomy , nephrotomy , digestive organ resection , etc . ) may affect pharmacokinetic profile lenvatinib 4 . Subjects know history clinically significant drug food allergy presently experience significant seasonal allergy 5 . Subjects experience weight loss gain great 10 % screen prior dose 6 . Subjects clinically abnormal symptom organ impairment find medical history , symptoms/signs , vital sign , ECG finding , laboratory test result require medical treatment 7 . Subjects QTc interval great 450 m screen checkin 8 . Subjects hemoglobin level le 12.0 g/dL 9 . Subjects positive result human immunodeficiency virus ( HIV ) hepatitis C virus antibody ( HCVAb ) screening test , clinical evidence active viral Hepatitis A B 10 . Subjects know suspected history drug alcohol misuse within 6 month prior screen , positive urine drug alcohol test screen baseline 11 . Subjects consume caffeinated beverage within 72 hour prior baseline 12 . Subjects take dietary supplement , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter [ e.g. , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice ) , vegetables mustard green family ( e.g. , kale , broccoli , watercress , collard green , kohlrabi , brussel sprout , mustard ) , charbroiled meat ] within 2 week prior dose 13 . Subjects take herbal preparation contain St. John 's Wort within 4 week prior dose 14 . Subjects take prescription drug within 4 week prior screen ( however , use prescription contraceptive product permit ) 15 . Subjects take overthecounter ( OTC ) medication within 2 week prior dose 16 . Subjects participate another clinical trial investigational drug device within 4 week prior dose 17 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within 1 week dose 18 . Subjects engage heavy exercise within 2 week prior checkin ( e.g. , marathon runner , weight lifter , etc . ) 19 . Subjects unwilling unable abide requirement study 20 . Subjects condition would make him/her , opinion investigator , unsuitable study , opinion investigator , likely complete study reason 21 . Known intolerance study drug excipients 22 . Females either pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>